Thoratec is redesigning its own next-generation device, called HeartMate III, to make it smaller, said Chief Executive Officer Gary Burbach in an interview. Burbach didn't say when it might be ready for human trials. Thoratec may supplement its pipeline by licensing or purchasing a new device, and rivals won't hurt Thoratec's revenue potential, he said.
``It's not a zero sum game,'' Burbach said. ``There is a tremendous opportunity for growth for ourselves as well as for successful competitive devices.''
HTW Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
